Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.1.3.9 (glucose-6-phosphatase)
 3,081 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Glucocorticoids significantly affected the developmental appearance of fructose-1,6-bisphosphatase [EC 3.1.3.11] and glucose-6-phosphatase [EC 3.1.3.9] in fetal mouse liver. In fragments of 15- or 16-day-old fetal livers maintained in organ culture in the absence of serum, induction of the bisphosphatase by dibutyryl cyclic AMP was repressed completely when the tissue was treated with 10(-7)M dexamethasone for 24 h during the second day of culture. The induction of the glucose phosphatase was greatly stimulated after a lag of 1 to 2 days. The glucocorticoid action continued over a period of 2 days even though the steroid had been washed out. The dose response curve of hydrocortisone with the half-maximally effective concentration of roughly 2 X 10(-8)M is in the physiological range. The corticoid action was specific for glucocorticoids, and aldosterone or progesterone was ineffective. When the tissue was cultured for 4 days before addition of dexamethasone, the bisphosphatase induction became insensitive to the steroid. Glucose-6-phosphatase induction, however, remained sensitive, but the long latent period required for the appearance of the hormone action disappeared. These results indicate the involvement of glucocorticoids in the developmental appearance of glucose-6-phosphatase in fetal liver.
 ...
PMID:Effect of glucocorticoids on induction of fructose bisphosphatase and glucose-6-phosphatase in fetal mouse liver. 609 79

Primary aldosteronism is associated with glucose intolerance and diabetes, which is due in part to impaired insulin release caused by reduction of potassium, although other possibilities remain to be elucidated. To evaluate the in vivo effects of aldosterone on glucose metabolism, a single dose of aldosterone was administered to mice, which resulted in elevation of the blood glucose level. In primary cultured mouse hepatocytes, the gene expression of gluconeogenic enzymes such as glucose-6-phosphatase (G6Pase), fructose-1,6-bisphosphatase and phosphoenolpyruvate carboxykinase increased in response to aldosterone in a dose-dependent manner even at a concentration similar to a physiological condition (10(-9) M). The inhibitory effect of insulin on G6Pase gene expression was partially suppressed by aldosterone. Furthermore, aldosterone enhanced G6Pase promoter activity in human hepatoma cell line HepG2, which was prevented by co-treatment with a glucocorticoid antagonist RU-486, but not a mineralocorticoid antagonist spironolactone. In contrast, aldosterone had no effects on major insulin signaling pathways including insulin receptor substrate-1, protein kinase B, and forkhead transcription factor. These results suggest that aldosterone may affect the inhibitory effect of insulin on hepatic gluconeogenesis through the glucocorticoid receptor, which may be one of the causes of impaired glucose metabolism in primary aldosteronism.
 ...
PMID:Aldosterone stimulates gene expression of hepatic gluconeogenic enzymes through the glucocorticoid receptor in a manner independent of the protein kinase B cascade. 1511 77

Type Iota(a) glycogen storage disease (GSD Iota(a)) is caused by the deficiency of glucose-6-phosphatase activity, which results in metabolic disorder and organ failure, including renal failure. GSD Iota(a) patients are generally diagnosed at a median age of 6 months. However, we report a 20-year-old Japanese female with newly diagnosed GSD Iota(a) . The renal disorder of GSD Iota(a) is considered to be produced by glomerular hyperfiltration, TGF-beta expression which is induced by renin-angiotensin-aldosterone system (RAS) and uric acid, and the increase in both small dense LDL and modified LDL which is characteristic of GSD Iota(a) as well as hypertriglyceridemia. With the administration of intensive therapies, including angiotensin type 1-receptor blocker and some lipid lowering drugs, along with traditional dietary therapy, daily proteinuria of the patient improved from 2.1 g to 0.78 g. Although the patients of GSD Iota(a) should receive an early and accurate diagnosis and effective therapies before the age of 1 year, the combination of traditional dietary therapies and intensive therapies may have therapeutic potential for the complications of adult patients. In this report, we describe the management of renal disease and the characteristic features of this metabolic disorder.
 ...
PMID:Early diagnosis and treatment may prevent the development of complications in an adult patient with glycogen storage disease type Ia. 2072 Mar 60